Cholesterol Drug Enhances T Cell Role in Melanoma ⁤Treatment

Updated June 16, 2025
⁤

philadelphia — Researchers at The ⁤Wistar Institute ⁢have found a simple intervention that could substantially⁣ improve the effectiveness of cell-based⁢ therapies, which use specially ‍designed T cells to combat cancer. The team, led by Dr. Hildegund C.J. Ertl, demonstrated that fenofibrate, a common cholesterol-lowering drug, can ⁣enhance T cells’ ability to destroy human tumors.

The study, published in Molecular Therapy Oncolytics, explored how to overcome limitations in treating solid ⁤tumors like ‍melanoma with CD8+ T cells. While these T cells are effective against ⁢liquid tumors, thier function ⁢can be hampered in solid tumors. The cancer cells hijack the T cells’ energy source, glycolysis, leading to T cell ‍exhaustion and⁤ tumor growth.

Ertl’s team discovered that ⁢fenofibrate forces T cells to use fatty acid ⁣oxidation⁤ (FAO) rather of glycolysis. This metabolic switch provides T cells‍ with an energy source that ‍cancer cells cannot⁢ exploit.⁣ The result: enhanced cancer-killing power against cancerous⁤ cell lines and solid human‍ tumor masses in preclinical models.

The researchers treated T cells with fenofibrate and observed that these T ⁤cells survived longer and killed more cancer⁤ cells compared to untreated T cells.

“Treating T ⁤cells⁤ with fenofibrate before‍ using them as a cancer treatment flips a switch ⁣of sorts in⁤ their metabolism,” said ⁤Dr. Hildegund Ertl. “Once ⁤that switch ‍is flipped, T cells can destroy the cancer much more effectively. And we’ve‍ confirmed that this holds for larger human tumor masses.”
⁢

What’s next

Ertl and her team believe this intervention holds ‍significant potential for future anti-tumor therapies,⁤ particularly for⁤ melanoma, ⁤the most hazardous form⁣ of ‍skin cancer.‍ The simple pre-treatment step⁣ could make a substantial difference in cancer treatment ⁢outcomes.